Literature DB >> 2445990

Cerebrospinal fluid monoamines in Down's syndrome adults at different ages.

M B Schapiro1, A D Kay, C May, A K Ryker, J V Haxby, S Kaufman, S Milstien, S I Rapoport.   

Abstract

Markers of monoamine metabolism in lumbar cerebrospinal fluid (CSF) and plasma were determined in nine young, healthy adults with trisomy 21 Down's syndrome (DS), 21-34-years-old, and in three DS subjects over 45 years, two of whom were demented, as well as in two groups of age-matched controls. Test scores of general intelligence, visuospatial ability, visual discrimination and verbal intelligence were reduced significantly in the old as compared to the young DS subjects. Dementia in DS was evident from a history of mental deterioration, disorientation and hallucinations. In the young DS adults, as compared to the controls, CSF 5-HIAA and norepinephrine were significantly elevated but plasma levels were unchanged. HVA, MHPG and biopterin did not differ between the DS groups and age-matched controls, or with relation to age in the DS or control subjects. These results suggest an increased turnover of monoamines in young adults with DS but that alterations in monoamine metabolism are unrelated to the cognitive decline with age in DS.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445990     DOI: 10.1111/j.1365-2788.1987.tb01369.x

Source DB:  PubMed          Journal:  J Ment Defic Res        ISSN: 0022-264X


  8 in total

1.  Alterations in the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain.

Authors:  J London; F K Ndiaye; L C Bui; B Souchet; F Daubigney; C Magnan; S Luquet; J Dairou; N Janel; C Rouch
Journal:  Mol Neurobiol       Date:  2018-09-20       Impact factor: 5.590

2.  Age, sex and mental retardation related changes of brainstem auditory evoked potentials in Down's syndrome.

Authors:  R Ferri; S Del Gracco; M Elia; S A Musumeci; M C Stefanini
Journal:  Ital J Neurol Sci       Date:  1995-09

3.  Plasma amino acids and neopterin in healthy persons with Down's syndrome.

Authors:  A W Coppus; D Fekkes; W M A Verhoeven; S Tuinier; J I M Egger; C M van Duijn
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

4.  Extrapyramidal features in advanced Down's syndrome: clinical evaluation and family history.

Authors:  P Vieregge; G Ziemens; M Freudenberg; A Piosinski; A Muysers; B Schulze
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

5.  Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome.

Authors:  Alain D Dekker; Juan Fortea; Rafael Blesa; Peter P De Deyn
Journal:  Alzheimers Dement (Amst)       Date:  2017-03-20

6.  Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease.

Authors:  Alain D Dekker; Yannick Vermeiren; Maria Carmona-Iragui; Bessy Benejam; Laura Videla; Ellen Gelpi; Tony Aerts; Debby Van Dam; Susana Fernández; Alberto Lleó; Sebastian Videla; Anne Sieben; Jean-Jacques Martin; Rafael Blesa; Juan Fortea; Peter P De Deyn
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-23

7.  Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging.

Authors:  Nathan Duval; Guido N Vacano; David Patterson
Journal:  Front Aging Neurosci       Date:  2018-09-06       Impact factor: 5.750

8.  Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models.

Authors:  Alain D Dekker; Yannick Vermeiren; Christelle Albac; Eva Lana-Elola; Sheona Watson-Scales; Dorota Gibbins; Tony Aerts; Debby Van Dam; Elizabeth M C Fisher; Victor L J Tybulewicz; Marie-Claude Potier; Peter P De Deyn
Journal:  Neurobiol Dis       Date:  2017-06-15       Impact factor: 5.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.